A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Inclusion Criteria:

• BMI ≥27 kg/m2 and ≤38.0 kg/m2 (inclusive) at screening

• For participants in Part A and B, no history of clinically significant diseases orclinically significant findings from the physical examination. For participants inPart C, no clinically significant diseases except T2DM, well controlledhypertension, and/or dyslipidemia.

• For participants in Part C, diagnosed with T2DM for at least 3 months beforescreening.

• For participants in Part C, T2DM includes glycated hemoglobin (HbA1c) value ≤10.5%at Screening and treated with stable therapy for at least 30 days prior toScreening/Visit 1.

Exclusion Criteria:

• Female who is lactating or who is pregnant according to the pregnancy test atScreening or on Day 1.

• Seated blood pressure higher than 160/100 mmHg at the Screening visit or prior tothe first study drug administration.

• Elevated resting pulse greater than 100 beats per minute at Screening visit or priorto the first study drug administration.

• Estimated glomerular filtration rate (eGFR) <80 mL/min at the Screening visit.

• Diagnosis of Type 1 diabetes.

• For Part A and Part B: Diagnosis of T2DM or glycated hemoglobin (HbA1c) > 6.4% orfasting plasma glucose >126 mg/dL at the Screening visit or history of taking anymedications to lower glucose.

• For Part A and Part B: Participant reported weight-related comorbidity, includingsleep apnea and cardiovascular disease.

• History of bariatric or weight loss surgeries.

• Personal or family history of medullary thyroid carcinoma or multiple endocrineneoplasia syndrome.

• Lifetime history of acute or chronic pancreatitis or pancreatic cancer.

• Participation in a weight loss program with or without pharmacotherapy during the 3months prior to study administration or plans to do so.